<html>
<head>
    <script language="JavaScript" src="http://code.jquery.com/jquery-1.4.4.js"></script>
    <script language="JavaScript" src="../js/pie.js"></script>
    <script language="JavaScript" src="../js/browser_adjust.js"></script>
    <script language="JavaScript" src="../js/search.js"></script>


    <script type="text/JavaScript">
    <!--

    var array = [[10.6927975994, "../topics/{product,_candidate,_development}.html", "{product,_candidate,_development}"], [4.6669461333, "../topics/{stock,_price,_share}.html", "{stock,_price,_share}"], [2.6962624875, "../topics/{provision,_law,_control}.html", "{provision,_law,_control}"], [2.6958131417, "../topics/{personnel,_key,_retain}.html", "{personnel,_key,_retain}"], [1.7011755221, "../topics/{product,_liability,_claim}.html", "{product,_liability,_claim}"], [1.6963250936, "../topics/{acquisition,_growth,_future}.html", "{acquisition,_growth,_future}"], [1.6962632849, "../topics/{property,_intellectual,_protect}.html", "{property,_intellectual,_protect}"], [1.6962621077, "../topics/{financial,_litigation,_operation}.html", "{financial,_litigation,_operation}"], [1.6962364503, "../topics/{cost,_regulation,_environmental}.html", "{cost,_regulation,_environmental}"], [1.695824444, "../topics/{loan,_real,_estate}.html", "{loan,_real,_estate}"]];
    var elements = generate_pie_elements(array);
    var piec = null;
    function init() {
        browser_adjust();
        
        // create pie chart
        piec = new PieChart(elements);
        piec.initialize();

    }

    function highlight(i) {
        piec.highlight(i);
    }
    
    function unhighlight() {
        piec.unhighlight();
    }
    //-->
    </script>

    <meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
    
    <title>1109196--3/2/2009--TELIK_INC</title>

    <link href="../styling.css" rel="stylesheet" type="text/css">
</head>

<body onLoad="init()">
<div id="navigation">
<hr noshade>
<table><tr>
    <td class="navtext">Browse&nbsp;&#x25B8;</td> 
    <td class="linked"><a>Topics</a>
      <ul> 
        <li><a href="../browse/topic-list.html">List of Terms</a></li> 
        <li><a href="../browse/topic-graph.html">Term Distributions</a></li> 
        <li><a href="../browse/topic-presence.html">Relative Presence</a></li>
      </ul> 
    </td> 
    <td class="linked"><a>Documents</a>
      <ul>
        <li><a href="../browse/doc-graph.html">Topic Distributions</a></li>
      </ul> 
    </td>
    <td class="linked"><a>Terms</a>
      <ul> 
        <li><a href="../browse/term-list.html">List by Frequency</a></li> 
        <li><a href="../browse/term-graph.html">Topic Distributions</a></li> 
       </ul> 
    </td>
    <td class="linked"><a>About</a>
      <ul>
        <li><a href="http://www.cs.princeton.edu/~blei/lda-c/">LDA</a></li>
      </ul> 
    </td>
    
    </td>
    <td></td>
    <td class="searchbar"> Search&nbsp;&#x25B8;</td>
    <td class="searchbar"><input type="text" name="search" size="20" onkeypress="handleKeyPress(event)"><span onclick="doSearch()"></span>
    </td>
</tr></table>
</div>

    <div id="top"></div>

    <h1 id="header">
        <table><tr>
            <td id="title">1109196--3/2/2009--TELIK_INC</td>
        </tr></table>

        <hr noshade>
    </h1>

    <div id="main">
        <table><tr>
            <td width="210px">
                <table class="dark">
                <tr><td><canvas id="canvas" width="200" height="200"></canvas></td></tr>
                <tr class="title">
                    <td>related topics</td>
                </tr>
                <tr class="list"><td id="{product,_candidate,_development}" onmouseover="highlight(0)" onmouseout="unhighlight()" onclick="window.location.href='../topics/{product,_candidate,_development}.html'">{product, candidate, development}</td></tr>
<tr class="list"><td id="{stock,_price,_share}" onmouseover="highlight(1)" onmouseout="unhighlight()" onclick="window.location.href='../topics/{stock,_price,_share}.html'">{stock, price, share}</td></tr>
<tr class="list"><td id="{provision,_law,_control}" onmouseover="highlight(2)" onmouseout="unhighlight()" onclick="window.location.href='../topics/{provision,_law,_control}.html'">{provision, law, control}</td></tr>
<tr class="list"><td id="{personnel,_key,_retain}" onmouseover="highlight(3)" onmouseout="unhighlight()" onclick="window.location.href='../topics/{personnel,_key,_retain}.html'">{personnel, key, retain}</td></tr>
<tr class="list"><td id="{product,_liability,_claim}" onmouseover="highlight(4)" onmouseout="unhighlight()" onclick="window.location.href='../topics/{product,_liability,_claim}.html'">{product, liability, claim}</td></tr>
<tr class="list"><td id="{acquisition,_growth,_future}" onmouseover="highlight(5)" onmouseout="unhighlight()" onclick="window.location.href='../topics/{acquisition,_growth,_future}.html'">{acquisition, growth, future}</td></tr>
<tr class="list"><td id="{property,_intellectual,_protect}" onmouseover="highlight(6)" onmouseout="unhighlight()" onclick="window.location.href='../topics/{property,_intellectual,_protect}.html'">{property, intellectual, protect}</td></tr>
<tr class="list"><td id="{financial,_litigation,_operation}" onmouseover="highlight(7)" onmouseout="unhighlight()" onclick="window.location.href='../topics/{financial,_litigation,_operation}.html'">{financial, litigation, operation}</td></tr>
<tr class="list"><td id="{cost,_regulation,_environmental}" onmouseover="highlight(8)" onmouseout="unhighlight()" onclick="window.location.href='../topics/{cost,_regulation,_environmental}.html'">{cost, regulation, environmental}</td></tr>
<tr class="list"><td id="{loan,_real,_estate}" onmouseover="highlight(9)" onmouseout="unhighlight()" onclick="window.location.href='../topics/{loan,_real,_estate}.html'">{loan, real, estate}</td></tr>

                </table>
            </td>

            <td>
                <table class="light">
                <tr class="doc"><td>
                    We have a history of net losses, which we expect to continue for the next several years. We will never be profitable unless we develop, and obtain regulatory approval and market acceptance of, our product candidates.
All of our product candidates are in research and development. If clinical trials of TELCYTA or TELINTRA are delayed or unsuccessful or if we are unable to complete the preclinical development of our other preclinical product candidates, our business may suffer.
If we do not find collaborators for our product candidates, we may have to reduce or delay our rate of product development and/or increase our expenditures.
We will depend on collaborative arrangements to complete the development and commercialization of some of our product candidates. These collaborative arrangements may place the development of our product candidates outside of our control, may require us to relinquish important rights or may otherwise not be on terms favorable to us.
If we are unable to raise adequate funds in the future, we will not be able to continue to fund our operations, research programs, preclinical testing and clinical trials to develop and manufacture our product candidates.
We believe that our ability to compete depends, in part, on our ability to use our proprietary TRAP technology to discover new pharmaceutical products.
The investment of our substantial cash balance and our investments in marketable debt securities are subject to risks, have resulted in a lack of liquidity which may cause losses and continue to affect the liquidity of these investments.
Raising additional capital by issuing securities or through collaboration and licensing arrangements may cause dilution to existing stockholders or require us to relinquish rights to our technologies or product candidates.
Our restructuring efforts may have an adverse impact on our current employees and on our ability to retain and attract future employees.
If our competitors develop and market products that are more effective than our product candidates or any products that we may develop, or obtain marketing approval before we do, our commercial opportunity will be reduced or eliminated.
If we do not obtain regulatory approval to market products in the United States and foreign countries, we or our collaborators will not be permitted to commercialize our product candidates.
As our product programs advance, we may need to hire additional scientific and management personnel. Our research and development efforts will be seriously jeopardized if we are unable to attract and retain key personnel.
If we or our licensees cannot obtain and defend our respective intellectual property rights, or if our product candidates, technologies or any products that we may develop are found to infringe patents of third parties, we could become involved in lengthy and costly legal proceedings that could adversely affect our business.
If we are unable to enter into or maintain existing contracts with third parties to manufacture our product candidates or any products that we may develop in sufficient quantities and at an acceptable cost, clinical development of product candidates could be delayed and we may be unable to meet demand for any products that we may develop and lose potential revenue.
Working capital constraints may force us to delay our efforts to develop certain product candidates in favor of developing others, which may prevent us from commercializing all product candidates as quickly as possible.
If product liability lawsuits are successfully brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates and any products that we may develop.
If we use biological and hazardous materials in a manner that causes injury, we may be liable for damages.
We have implemented anti-takeover provisions which could discourage or prevent a takeover, even if an acquisition would be beneficial to our stockholders and may prevent attempts by our stockholders to replace or remove our current management.
We adopted a stockholder rights plan that may discourage, delay or prevent a merger or acquisition that is beneficial to our stockholders.
Substantial future sales of our common stock by us or by our existing stockholders could cause our stock price to fall.
If we do not progress in our programs as anticipated, our stock price could decrease.
Our stock price may be volatile, you may not be able to resell your shares at or above your purchase price.
Our stock price may not meet the minimum bid price for continued listing on the Nasdaq Global Market. Our ability to publicly or privately sell equity securities and the liquidity of our common stock could be adversely affected if we are delisted from The Nasdaq Global Market or if we are unable to transfer our listing to another stock market.
We have been, and in the future may be, subject to securities class action lawsuits and shareholder derivative actions. These, and potential similar or related litigation, could result in substantial damages and may divert management s time and attention from our business.
<p><a href="http://www.sec.gov/Archives/edgar/data/1109196/0001193125-09-042696.txt">Full 10-K form&nbsp;&#x25B8;</a></p>
                </td></tr>
                </table>
            </td>

            <td width="25%">
                <table class="dark">
                <tr class="title">
                    <td>related documents</td>
                </tr>
                <tr class="list"><td onclick="window.location.href='../docs/1109196--3-2-2010--TELIK_INC.html'">1109196--3/2/2010--TELIK_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1109196--2-28-2007--TELIK_INC.html'">1109196--2/28/2007--TELIK_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1109196--3-3-2006--TELIK_INC.html'">1109196--3/3/2006--TELIK_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/887359--9-13-2007--AASTROM_BIOSCIENCES_INC.html'">887359--9/13/2007--AASTROM_BIOSCIENCES_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/911216--9-13-2006--PALATIN_TECHNOLOGIES_INC.html'">911216--9/13/2006--PALATIN_TECHNOLOGIES_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/911216--9-29-2008--PALATIN_TECHNOLOGIES_INC.html'">911216--9/29/2008--PALATIN_TECHNOLOGIES_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/880643--2-13-2009--GENTA_INC_DE-.html'">880643--2/13/2009--GENTA_INC_DE/</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/880643--3-17-2008--GENTA_INC_DE-.html'">880643--3/17/2008--GENTA_INC_DE/</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/921114--3-29-2007--TARGETED_GENETICS_CORP_-WA-.html'">921114--3/29/2007--TARGETED_GENETICS_CORP_/WA/</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1034842--3-7-2008--RIGEL_PHARMACEUTICALS_INC.html'">1034842--3/7/2008--RIGEL_PHARMACEUTICALS_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1034842--3-2-2010--RIGEL_PHARMACEUTICALS_INC.html'">1034842--3/2/2010--RIGEL_PHARMACEUTICALS_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/12239--3-30-2009--SPHERIX_INC.html'">12239--3/30/2009--SPHERIX_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/878903--3-22-2007--ALTEON_INC_-DE.html'">878903--3/22/2007--ALTEON_INC_/DE</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/744218--3-16-2007--AVANT_IMMUNOTHERAPEUTICS_INC.html'">744218--3/16/2007--AVANT_IMMUNOTHERAPEUTICS_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/914475--2-8-2010--NEUROCRINE_BIOSCIENCES_INC.html'">914475--2/8/2010--NEUROCRINE_BIOSCIENCES_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/744218--3-16-2006--AVANT_IMMUNOTHERAPEUTICS_INC.html'">744218--3/16/2006--AVANT_IMMUNOTHERAPEUTICS_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/357097--3-7-2008--ISOLAGEN_INC.html'">357097--3/7/2008--ISOLAGEN_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1034842--3-8-2006--RIGEL_PHARMACEUTICALS_INC.html'">1034842--3/8/2006--RIGEL_PHARMACEUTICALS_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1034842--3-8-2007--RIGEL_PHARMACEUTICALS_INC.html'">1034842--3/8/2007--RIGEL_PHARMACEUTICALS_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1060736--3-12-2010--SEATTLE_GENETICS_INC_-WA.html'">1060736--3/12/2010--SEATTLE_GENETICS_INC_/WA</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1055726--3-31-2009--INOVIO_BIOMEDICAL_CORP.html'">1055726--3/31/2009--INOVIO_BIOMEDICAL_CORP</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/12239--3-30-2010--SPHERIX_INC.html'">12239--3/30/2010--SPHERIX_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/927829--3-6-2008--NITROMED_INC.html'">927829--3/6/2008--NITROMED_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1082554--2-28-2007--UNITED_THERAPEUTICS_CORP.html'">1082554--2/28/2007--UNITED_THERAPEUTICS_CORP</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/887359--9-7-2010--AASTROM_BIOSCIENCES_INC.html'">887359--9/7/2010--AASTROM_BIOSCIENCES_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/875320--3-16-2006--VERTEX_PHARMACEUTICALS_INC_-_MA.html'">875320--3/16/2006--VERTEX_PHARMACEUTICALS_INC_/_MA</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/887359--9-13-2006--AASTROM_BIOSCIENCES_INC.html'">887359--9/13/2006--AASTROM_BIOSCIENCES_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/891293--3-16-2006--CELL_THERAPEUTICS_INC.html'">891293--3/16/2006--CELL_THERAPEUTICS_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1123695--3-9-2009--IMARX_THERAPEUTICS_INC.html'">1123695--3/9/2009--IMARX_THERAPEUTICS_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1118361--3-14-2006--RENOVIS_INC.html'">1118361--3/14/2006--RENOVIS_INC</td></tr>

                </table>
            </td>
        </tr></table>
    </div>

    <div id="footer">
        <br>
        <hr noshade>
    </div>
</body>
</html>
